Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers
PARP抑制剂奥拉帕尼和AKT抑制剂卡帕替尼治疗BRCA1/2突变型和非BRCA1/2突变型癌症患者的I期试验
期刊:Cancer Discovery
影响因子:33.3
doi:10.1158/2159-8290.CD-20-0163
Yap, Timothy A; Kristeleit, Rebecca; Michalarea, Vasiliki; Pettitt, Stephen J; Lim, Joline S J; Carreira, Suzanne; Roda, Desamparados; Miller, Rowan; Riisnaes, Ruth; Miranda, Susana; Figueiredo, Ines; Rodrigues, Daniel Nava; Ward, Sarah; Matthews, Ruth; Parmar, Mona; Turner, Alison; Tunariu, Nina; Chopra, Neha; Gevensleben, Heidrun; Turner, Nicholas C; Ruddle, Ruth; Raynaud, Florence I; Decordova, Shaun; Swales, Karen E; Finneran, Laura; Hall, Emma; Rugman, Paul; Lindemann, Justin P O; Foxley, Andrew; Lord, Christopher J; Banerji, Udai; Plummer, Ruth; Basu, Bristi; Lopez, Juanita S; Drew, Yvette; de Bono, Johann S